When prescribing antidepressants to pregnant women, what is the primary concern?

The primary concern when prescribing antidepressants to pregnant women is the potential risk of fetal exposure. This concern arises because many medications can cross the placenta and affect fetal development. Research has shown that antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), may carry risks such as congenital malformations, preterm birth, and other developmental issues. Hence, the benefits of treating maternal depression must be carefully weighed against these risks to the fetus.

It is crucial for healthcare providers to consider both the type of antidepressant prescribed and the timing of exposure during pregnancy. Some medications may be safer than others, and in some cases, the risks associated with untreated maternal depression may outweigh the risks of medication exposure. Thus, ongoing monitoring and collaboration with a specialist in maternal-fetal medicine may be warranted to ensure the safety and well-being of both the mother and the developing fetus.